DrugOct 12, 2022
Arformoterol Tartrate Inhalation Solution, 15 mcg/2mL, 2 mL Sterile Unit-Dose Vial recall — FDA D-1550-2022
Lack of Assurance of Sterility: environmental monitoring failure.
Class IIFDA: TerminatedCIPLA
Recall history in this database
Classification mix: Class II: 4.
DrugOct 5, 2022
Budesonide Inhalation Suspension 0.25mg/2mL, For Inhalation Only recall — FDA D-1545-2022
Lack of Assurance of Sterility
Class IIFDA: TerminatedCIPLA
DrugSep 14, 2022
CIPLA Difluprednate Ophthalmic Emulsion, 0.05%, 5 mL bottle recall — FDA D-1498-2022
Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.
Class IIFDA: TerminatedCIPLA
DrugSep 14, 2022
Difluprednate Ophthalmic Emulsion, 0.05%, 5 mL bottle recall — FDA D-1499-2022
Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.
Class IIFDA: TerminatedCIPLA
Understanding this recall history
This page summarizes recall records in which the official source identifies CIPLA as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.